NCT01381809 An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes Status COMPLETED Phase PHASE3
NCT01350245 Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor Status COMPLETED Phase PHASE2
NCT01324960 Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes Status WITHDRAWN Phase PHASE1/PHASE2
NCT01302106 Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes Status WITHDRAWN Phase PHASE2
NCT01246076 Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents Status COMPLETED Phase PHASE2
NCT01241500 Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Status COMPLETED Phase PHASE3
NCT01211457 Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Status UNKNOWN Phase PHASE1/PHASE2
NCT01201811 Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) Status COMPLETED Phase PHASE4
NCT01186939 An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS) Status COMPLETED Phase PHASE3
NCT01165996 Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome Status COMPLETED Phase PHASE1/PHASE2
NCT01164163 INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Status COMPLETED Phase PHASE1
NCT01158118 Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors Status COMPLETED Phase PHASE2
NCT01137643 Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer Status RECRUITING Phase N/A
NCT01129739 Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic Syndromes Status UNKNOWN Phase PHASE2
NCT01118013 Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant Status TERMINATED Phase PHASE2